A new study published in Biomed Pharmacotherapy finds that cannabidivarin (CBDV), a non-psychoactive cannabinoid, may have significant potential as an immunotherapy agent for cancer. Researchers at the Technion-Israel Institute of Technology found that CBDV directly reprograms myeloid suppressor cells, which are key drivers of immunosuppression in the tumor microenvironment. These cells, including Myeloid-Derived Suppressor Cells … Continue reading Cannabidivarin (CBDV) May Enhance Immune Response Against Cancer by Targeting Suppressor Cells, Study Finds